NeuBase Therapeutics, Inc. - FORM 10-K - EX-10.8(B) - AMENDMENT TO 2014 STOCK INCENTIVE PLAN - December 14, 2015

Attached files

file filename
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - NeuBase Therapeutics, Inc.ex23.htm
EX-14 - CODE OF ETHICS - NeuBase Therapeutics, Inc.ex14.htm
EX-21 - LIST OF SUBSIDIARIES OF OHR PHARMACEUTICAL. INC. - NeuBase Therapeutics, Inc.ex21.htm
EX-31.2 - CHIEF FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex32-1.htm
EX-32.2 - CHIEF FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER - NeuBase Therapeutics, Inc.ex32-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-10.2(E) - LOCK-UP AGREEMENT - NeuBase Therapeutics, Inc.ex10-2e.htm
EX-10.2(D) - RESTRICTED STOCK AGREEMENT - NeuBase Therapeutics, Inc.ex10-2d.htm
EX-10.2(C) - CONSULTING AGREEMENT AND RELEASE - NeuBase Therapeutics, Inc.ex10-2c.htm
EX-10.3(C) - PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT - NeuBase Therapeutics, Inc.ex10-3c.htm
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohrp-10k_093015.htm
EX-10.2(F) - PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT - NeuBase Therapeutics, Inc.ex10-2f.htm

 

Ohr Pharmaceutical, Inc. 10-K

 

 

Exhibit 10.8(b)

 

FIRST AMENDMENT

TO
OHR PHARMACEUTICAL, INC.

AMENDED AND RESTATED 2014 STOCK INCENTIVE PLAN

 

 

This First Amendment (this “Amendment”) is to be effective as of March 31, 2014.

 

1. Section 4(a) of the Ohr Pharmaceutical, Inc. 2014 Stock Incentive Plan is amended and restated in its entirety as follows:

 

“(a) Number of Shares Available for Awards. The shares subject to Awards granted under the Plan shall be 2,750,000 Shares. Such Shares subject to the Plan may be either authorized and unissued Shares (which will not be subject to preemptive rights) or previously issued Shares acquired by the Company or any Affiliate.

 

2. This Amendment was duly adopted and approved by the Board of Directors of Ohr Pharmaceutical, Inc. (the “Company”) on January 6, 2015 and by the stockholders of the Company on March 10, 2015.

 

 

 

 

 

 

 

NeuBase Therapeutics, Inc. Reports